4//SEC Filing
Patel Naimish 4
Accession 0000950170-25-079822
CIK 0001674416other
Filed
May 29, 8:00 PM ET
Accepted
May 30, 5:00 PM ET
Size
8.8 KB
Accession
0000950170-25-079822
Insider Transaction Report
Form 4
Patel Naimish
Chief Medical Officer
Transactions
- Sale
Common Shares
2025-05-29$35.94/sh−3,932$141,316→ 6,068 total - Exercise/Conversion
Restricted Stock Units
2025-05-28−10,000→ 30,000 total→ Common Shares (10,000 underlying) - Exercise/Conversion
Common Shares
2025-05-28+10,000→ 10,000 total
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F2]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
- [F3]This restricted stock unit award was granted on May 28, 2024 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on May 28, 2025, (ii) one quarter of the shares vesting on May 28, 2026, (iii) one quarter of the shares vesting on May 28, 2027, and (iv) one quarter of the shares vesting on May 28, 2028.
Documents
Issuer
CRISPR Therapeutics AG
CIK 0001674416
Entity typeother
Related Parties
1- filerCIK 0002021679
Filing Metadata
- Form type
- 4
- Filed
- May 29, 8:00 PM ET
- Accepted
- May 30, 5:00 PM ET
- Size
- 8.8 KB